A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC)

Lanell M. Peterson, Brenda F. Kurland, Erin K. Schubert, Jeanne M. Link, V. K. Gadi, Jennifer M. Specht, Janet F. Eary, Peggy Porter, Lalitha K. Shankar, David A. Mankoff, Hannah M. Linden

Research output: Contribution to journalArticlepeer-review

58 Scopus citations


Purpose: 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) quantifies estrogen receptor (ER) expression in tumors and may provide diagnostic benefit. Procedures: Women with newly diagnosed metastatic breast cancer (MBC) from an ER-positive primary tumor were imaged before starting endocrine therapy. FES uptake was evaluated qualitatively and quantitatively, and associated with response and with ER expression. Results: Nineteen patients underwent FES imaging. Fifteen had a biopsy of a metastasis and 15 were evaluable for response. Five patients had quantitatively low FES uptake, six had at least one site of qualitatively FES-negative disease. All patients with an ER-negative biopsy had both low uptake and at least one site of FES-negative disease. Of response-evaluable patients, 2/2 with low FES standard uptake value tumors had progressive disease within 6 months, as did 2/3 with qualitatively FES-negative tumors. Conclusions: Low/absent FES uptake correlates with lack of ER expression. FES-positron emission tomography can help identify patients with endocrine resistant disease and safely measures ER in MBC.

Original languageEnglish (US)
Pages (from-to)431-440
Number of pages10
JournalMolecular Imaging and Biology
Issue number3
StatePublished - Jun 2014
Externally publishedYes


  • ER expression
  • Endocrine therapy
  • Metastatic breast cancer
  • Response

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research


Dive into the research topics of 'A phase 2 study of 16α-[<sup>18</sup>F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC)'. Together they form a unique fingerprint.

Cite this